CN105829299A - 抗癌剂及其制备 - Google Patents

抗癌剂及其制备 Download PDF

Info

Publication number
CN105829299A
CN105829299A CN201480070416.9A CN201480070416A CN105829299A CN 105829299 A CN105829299 A CN 105829299A CN 201480070416 A CN201480070416 A CN 201480070416A CN 105829299 A CN105829299 A CN 105829299A
Authority
CN
China
Prior art keywords
compound
alkyl
formula
independently selected
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480070416.9A
Other languages
English (en)
Chinese (zh)
Inventor
阿伦·K·高希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Priority to CN202110798232.6A priority Critical patent/CN113461705A/zh
Priority to CN202110798234.5A priority patent/CN113773333A/zh
Publication of CN105829299A publication Critical patent/CN105829299A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201480070416.9A 2013-11-19 2014-11-19 抗癌剂及其制备 Pending CN105829299A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110798232.6A CN113461705A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备
CN202110798234.5A CN113773333A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906133P 2013-11-19 2013-11-19
US61/906,133 2013-11-19
PCT/US2014/066458 WO2015077370A1 (en) 2013-11-19 2014-11-19 Anti-cancer agents and preparation thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110798234.5A Division CN113773333A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备
CN202110798232.6A Division CN113461705A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备

Publications (1)

Publication Number Publication Date
CN105829299A true CN105829299A (zh) 2016-08-03

Family

ID=53180106

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480070416.9A Pending CN105829299A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备
CN202110798232.6A Pending CN113461705A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备
CN202110798234.5A Pending CN113773333A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110798232.6A Pending CN113461705A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备
CN202110798234.5A Pending CN113773333A (zh) 2013-11-19 2014-11-19 抗癌剂及其制备

Country Status (20)

Country Link
US (1) US10000505B2 (cg-RX-API-DMAC10.html)
EP (1) EP3071563B1 (cg-RX-API-DMAC10.html)
JP (2) JP6937578B2 (cg-RX-API-DMAC10.html)
KR (1) KR102428737B1 (cg-RX-API-DMAC10.html)
CN (3) CN105829299A (cg-RX-API-DMAC10.html)
AU (1) AU2014353087B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016011430B1 (cg-RX-API-DMAC10.html)
CA (1) CA2931111C (cg-RX-API-DMAC10.html)
CL (1) CL2016001209A1 (cg-RX-API-DMAC10.html)
DK (1) DK3071563T3 (cg-RX-API-DMAC10.html)
EA (1) EA035262B1 (cg-RX-API-DMAC10.html)
ES (1) ES2943711T3 (cg-RX-API-DMAC10.html)
FI (1) FI3071563T3 (cg-RX-API-DMAC10.html)
IL (2) IL282430B2 (cg-RX-API-DMAC10.html)
MX (1) MX375896B (cg-RX-API-DMAC10.html)
MY (1) MY189459A (cg-RX-API-DMAC10.html)
PE (1) PE20161240A1 (cg-RX-API-DMAC10.html)
PH (2) PH12021551085A1 (cg-RX-API-DMAC10.html)
PT (1) PT3071563T (cg-RX-API-DMAC10.html)
WO (1) WO2015077370A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
CN109020876A (zh) * 2018-09-21 2018-12-18 大连理工大学 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法
CN113563361A (zh) * 2021-08-17 2021-10-29 浙江珲达生物科技有限公司 一种从伯克霍尔德菌发酵液提取fr901464的方法
CN115698018A (zh) * 2020-04-09 2023-02-03 百时美施贵宝公司 美亚霉素类似物和使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468976A4 (en) * 2016-06-08 2019-11-27 William Marsh Rice University DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF
AU2017331260B2 (en) * 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309599B2 (en) * 2006-09-08 2012-11-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2013032693A2 (en) * 2011-08-27 2013-03-07 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses
WO2014068443A1 (en) * 2012-11-05 2014-05-08 Pfizer Inc. Spliceostatin analogs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
AR080234A1 (es) * 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309599B2 (en) * 2006-09-08 2012-11-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2013032693A2 (en) * 2011-08-27 2013-03-07 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses
WO2014068443A1 (en) * 2012-11-05 2014-05-08 Pfizer Inc. Spliceostatin analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARUN K. GHOSH,ET AL.,: "Enantioselective Syntheses of FR901464 and Spliceostatin A: Potent Inhibitors of Spliceosome", 《ORG. LETT.》 *
SAMI OSMAN,ET AL.,: "Structural Requirements for the Antiproliferative Activity of Pre-mRNA Splicing Inhibitor FR901464", 《CHEM. EUR. J.》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
CN109020876A (zh) * 2018-09-21 2018-12-18 大连理工大学 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法
CN115698018A (zh) * 2020-04-09 2023-02-03 百时美施贵宝公司 美亚霉素类似物和使用方法
CN113563361A (zh) * 2021-08-17 2021-10-29 浙江珲达生物科技有限公司 一种从伯克霍尔德菌发酵液提取fr901464的方法
WO2023020501A1 (zh) * 2021-08-17 2023-02-23 浙江珲达生物科技有限公司 一种从伯克霍尔德菌发酵液提取fr901464的方法

Also Published As

Publication number Publication date
JP2017503753A (ja) 2017-02-02
JP2019189644A (ja) 2019-10-31
EA201691010A1 (ru) 2016-11-30
US20160297831A1 (en) 2016-10-13
WO2015077370A1 (en) 2015-05-28
EP3071563A1 (en) 2016-09-28
PH12021551085A1 (en) 2023-07-17
BR112016011430A2 (pt) 2017-09-12
US10000505B2 (en) 2018-06-19
JP6937578B2 (ja) 2021-09-22
CN113461705A (zh) 2021-10-01
CA2931111C (en) 2022-03-15
IL245637A0 (en) 2016-06-30
AU2014353087B2 (en) 2018-07-19
CN113773333A (zh) 2021-12-10
EP3071563A4 (en) 2017-09-06
PT3071563T (pt) 2023-05-09
MY189459A (en) 2022-02-14
MX375896B (es) 2025-03-07
AU2014353087A1 (en) 2016-06-30
KR102428737B1 (ko) 2022-08-02
IL282430A (en) 2021-06-30
IL245637B (en) 2021-05-31
NZ721152A (en) 2022-03-25
CA2931111A1 (en) 2015-05-28
IL282430B2 (en) 2025-04-01
ES2943711T3 (es) 2023-06-15
BR112016011430B1 (pt) 2022-09-13
IL282430B1 (en) 2024-12-01
PH12016500924A1 (en) 2016-07-18
PE20161240A1 (es) 2016-11-27
JP6929903B2 (ja) 2021-09-01
MX2016006591A (es) 2017-05-30
FI3071563T3 (fi) 2023-05-29
EP3071563B1 (en) 2023-04-19
DK3071563T3 (da) 2023-05-08
NZ759166A (en) 2022-03-25
CL2016001209A1 (es) 2017-06-02
KR20160086411A (ko) 2016-07-19
EA035262B1 (ru) 2020-05-21

Similar Documents

Publication Publication Date Title
JP6929903B2 (ja) 抗癌剤およびその調製方法
US12435071B2 (en) Bryostatin compounds and methods of preparing the same
CN109665968A (zh) 并环化合物及其制备方法和用途
JP7641933B2 (ja) カリスポンジオリド、その類似体、およびそれらの使用
HK40062614A (en) Anti-cancer agents and preparation thereof
CN104583203B (zh) Schweinfurthin类似物
HK1227866B (en) Anti-cancer agents and preparation thereof
HK1227866A1 (en) Anti-cancer agents and preparation thereof
JP7111722B2 (ja) 抗がん剤およびその調製方法
NZ721152B2 (en) Anti-cancer agents and preparation thereof
NZ759166B2 (en) Anti-cancer agents and preparation thereof
WO2022040788A1 (en) Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity
WO2009153782A1 (en) Substituted cyclohexylidene-ethylidene-octahydro-indene compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160803

RJ01 Rejection of invention patent application after publication